Blockchain Registration Transaction Record

TransCode’s TTX-MC138 Shows Durable Disease Stabilization in Phase 1a Trial

TransCode Therapeutics reports Phase 1a results for TTX-MC138 showing durable disease stabilization in advanced cancer patients, supporting Phase 2a advancement. Learn more about RNAZ.

TransCode’s TTX-MC138 Shows Durable Disease Stabilization in Phase 1a Trial

This news matters because it brings hope to patients with advanced cancers that have limited treatment options. TTX-MC138 targets microRNA-10b, a biomarker of metastasis, offering a novel approach to stabilize disease and potentially improve outcomes. The safety profile and durable responses seen in the trial support progression to Phase 2a, bringing this therapy closer to clinical availability for those in need.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xbe93891ce8124fcb648d58f8e2deadecbf6351c638037660e3a811bffb8adfbb
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintxenoadMT-e3d6d8caa830943c431e281aee8ff37b